Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety cohort study of inhaled TQC3721 suspension in moderate to severe chronic obstructive pulmonary disease
CTR20260769Phase 3Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of TQC3721 in chronic obstructive pulmonary disease (COPD), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Apr 2026; status: active.
02
Drugs
TQC3721
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20260769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260769.